6185 Stock Overview
Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6185 from our risk checks.
CanSino Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$26.95 |
| 52 Week High | HK$36.85 |
| 52 Week Low | HK$14.80 |
| Beta | 0.49 |
| 11 Month Change | 5.48% |
| 3 Month Change | 64.33% |
| 1 Year Change | -1.28% |
| 33 Year Change | -82.42% |
| 5 Year Change | n/a |
| Change since IPO | -92.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6185 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -6.9% | -0.3% | -0.6% |
| 1Y | -1.3% | -15.2% | 9.6% |
Return vs Industry: 6185 exceeded the Hong Kong Biotechs industry which returned -13.1% over the past year.
Return vs Market: 6185 underperformed the Hong Kong Market which returned 10.1% over the past year.
Price Volatility
| 6185 volatility | |
|---|---|
| 6185 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 19.0% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 6185 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6185's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,149 | Xuefeng Yu | www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
| 6185 fundamental statistics | |
|---|---|
| Market cap | HK$11.21b |
| Earnings (TTM) | -HK$773.43m |
| Revenue (TTM) | HK$803.95m |
8.3x
P/S Ratio-8.6x
P/E RatioIs 6185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6185 income statement (TTM) | |
|---|---|
| Revenue | CN¥748.53m |
| Cost of Revenue | CN¥774.40m |
| Gross Profit | -CN¥25.87m |
| Other Expenses | CN¥694.25m |
| Earnings | -CN¥720.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Nov 25, 2024
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.46% |
| Net Profit Margin | -96.20% |
| Debt/Equity Ratio | 41.3% |
How did 6185 perform over the long term?
See historical performance and comparison